Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains

被引：0
|
作者：
机构：
[1] [1,Hay, Duncan A.
[2] 2,Fedorov, Oleg
[3] 2,Martin, Sarah
[4] 2,Singleton, Dean C.
[5] 2,Tallant, Cynthia
[6] 2,Wells, Christopher
[7] Picaud, Sarah
[8] 2,Philpott, Martin
[9] 2,Monteiro, Octovia P.
[10] 2,Rogers, Catherine M.
[11] Conway, Stuart J.
[12] Rooney, Timothy P. C.
[13] 2,Tumber, Anthony
[14] 2,Yapp, Clarence
[15] Filippakopoulos, Panagis
[16] Bunnage, Mark E.
[17] 2,Müller, Susanne
[18] 2,Knapp, Stefan
[19] Schofield, Christopher J.
[20] 2,Brennan, Paul E.
来源：
Brennan, P.E. (paul.brennan@sgc.ox.ac.uk) | 1600年 / American Chemical Society卷 / 136期
关键词：
Small-molecule inhibitors that target bromodomains outside of the bromodomain and extra-terminal (BET) sub-family are lacking. Here; we describe highly potent and selective ligands for the bromodomain module of the human lysine acetyl transferase CBP/p300; developed from a series of 5-isoxazolyl-benzimidazoles. Our starting point was a fragment hit; which was optimized into a more potent and selective lead using parallel synthesis employing Suzuki couplings; benzimidazole-forming reactions; and reductive aminations. The selectivity of the lead compound against other bromodomain family members was investigated using a thermal stability assay; which revealed some inhibition of the structurally related BET family members. To address the BET selectivity issue; X-ray crystal structures of the lead compound bound to the CREB binding protein (CBP) and the first bromodomain of BRD4 (BRD4(1)) were used to guide the design of more selective compounds. The crystal structures obtained revealed two distinct binding modes. By varying the aryl substitution pattern and developing conformationally constrained analogues; selectivity for CBP over BRD4(1) was increased. The optimized compound is highly potent (K d = 21 nM) and selective; displaying 40-fold selectivity over BRD4(1). Cellular activity was demonstrated using fluorescence recovery after photo-bleaching (FRAP) and a p53 reporter assay. The optimized compounds are cell-active and have nanomolar affinity for CBP/p300; therefore; they should be useful in studies investigating the biological roles of CBP and p300 and to validate the CBP and p300 bromodomains as therapeutic targets. © 2014 American Chemical Society;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Journal article (JA)
引用
收藏
相关论文
共 50 条
  • [21] Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells
    Uttarkar, Sagar
    Piontek, Therese
    Dukare, Sandeep
    Schomburg, Caroline
    Schlenke, Peter
    Berdel, Wolfgang E.
    Mueller-Tidow, Carsten
    Schmidt, Thomas J.
    Klempnauer, Karl-Heinz
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (12) : 2905 - 2915
  • [22] Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors
    Lu, Wenchao
    Xiong, Huan
    Chen, Yu
    Wang, Chen
    Zhang, Hao
    Xu, Pan
    Han, Jie
    Xiao, Senhao
    Ding, Hong
    Chen, Zhifeng
    Lu, Tian
    Wang, Jun
    Zhang, Yuanyuan
    Yue, Liyan
    Liu, Yu-Chih
    Zhang, Chenhua
    Yang, Yaxi
    Jiang, Hualiang
    Chen, Kaixian
    Zhou, Bing
    Luo, Cheng
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (20) : 5397 - 5407
  • [23] CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation
    Olzscha, Heidi
    Fedorov, Oleg
    Kessler, Benedikt M.
    Knapp, Stefan
    La Thangue, Nicholas B.
    CELL CHEMICAL BIOLOGY, 2017, 24 (01): : 9 - 23
  • [24] Discovery Small-Molecule p300 Inhibitors Derived from a Newly Developed Indazolone-Focused DNA-Encoded Library
    Suo, Yanrui
    Li, Kaige
    Ling, Xing
    Yan, Kenian
    Lu, Weiwei
    Yue, Jinfeng
    Chen, Xiaohua
    Duan, Zhiqiang
    Lu, Xiaojie
    BIOCONJUGATE CHEMISTRY, 2024, 35 (08) : 1251 - 1257
  • [25] Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers
    Abbineni, Chandrasekhar
    Thiyagarajan, Saravanan
    Aravind, A. B.
    Dhudashiya, Amit A.
    Marappan, Sivapriya
    Kumar, Naveen R.
    Raghavendra, N. R.
    Dey, Mamon
    Kumar, Avinash
    Bharathi, Uma B., V
    Renukappa, Girish Aggunda
    Reddy, N. Venkata Siva
    Babu, Asha
    Shetty, Aakanksha J.
    Amith, A.
    Rao, Narasimha K.
    Gore, Suraj T.
    Jaleel, Mahaboobi
    Senaiar, Ramesh S.
    Nataraj, Vijaya Shankar
    Mukherjee, Subhendu
    Samiulla, D. S.
    Antony, Thomas
    Daginakatte, Girish
    Eswarappa, Rajesh
    Nellore, Kavitha
    Chelur, Shekar
    Ramachandra, Murali
    Samajdar, Susanta
    CANCER RESEARCH, 2022, 82 (12)
  • [26] The important role of the histone acetyltransferases p300/CBP in cancer and the promising anticancer effects of p300/CBP inhibitors
    Xin Wu
    Xin Zhang
    Shaoshan Tang
    Yao Wang
    Cell Biology and Toxicology, 41 (1)
  • [27] HAT Trick: p300, Small Molecule, Inhibitor
    Ott, Melanie
    Verdin, Eric
    CHEMISTRY & BIOLOGY, 2010, 17 (05): : 417 - 418
  • [28] Small molecule modulators of histone acetyltransferase p300
    Balasubramanyam, K
    Swaminathan, V
    Ranganathan, A
    Kundu, TK
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (21) : 19134 - 19140
  • [29] p300/CBP keeps chromatin silent
    Wrighton, Katharine H.
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2022, 29 (11) : 1039 - 1039
  • [30] p300 and CBP: Partners for life and death
    Giordano, A
    Avantaggiati, ML
    JOURNAL OF CELLULAR PHYSIOLOGY, 1999, 181 (02) : 218 - 230
12345